BTG PLC Appointment of Non-executive Director (5273X)
27 November 2017 - 6:00PM
UK Regulatory
TIDMBTG
RNS Number : 5273X
BTG PLC
27 November 2017
BTG plc: Appointment of Non-executive Director
London, UK, 27 November 2017: BTG plc (LSE: BTG), the global
specialist healthcare company, today announces the appointment of
Gregory Barrett as a non-executive director of the Board.
Greg has a broad range of commercial experience in the US
medtech industry, with a focus on interventional medicine
therapies. He is currently a non-executive director of Cutera Inc
and was previously President and Chief Executive Officer of DFINE
Inc, Barrx Medical Inc, and ACMI Corporation. Prior roles include
leading a minimally invasive surgery division of Boston Scientific,
both in US and in emerging markets. Greg has also held a series of
senior sales and marketing roles at a number of companies including
Baxter Healthcare and C.R. Bard.
Garry Watts, BTG's Chairman, commented: "Greg brings a strong
track record to BTG, with significant US commercial and
international medtech experience, which will be of great benefit to
us as we continue to implement our growth plans."
There are no further details to be disclosed in relation to
paragraph 9.6.13R of the Financial Conduct Authority Listing
Rules.
For further information contact:
BTG
Andy Burrows, VP Corporate & Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605
Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536
Chris Sampson, Corporate Communications Director
+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178
FTI Consulting
Ben Atwell/Simon Conway
+44 (0)20 3727 1000
About BTG
BTG is a global specialist healthcare company bringing to market
innovative products in specialist areas of medicine to better serve
doctors and their patients. We have a portfolio of Interventional
Medicine products to advance the treatment of cancer, severe
emphysema, severe blood clots and varicose veins, and Specialty
Pharmaceuticals that help patients overexposed to certain
medications or toxins. Inspired by patient and physician needs, BTG
is investing to expand its portfolio to address some of today's
most complex healthcare challenges. To learn more about BTG, please
visit: btgplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOALLFSDLVLRFID
(END) Dow Jones Newswires
November 27, 2017 02:00 ET (07:00 GMT)
Btg (LSE:BTG)
Historical Stock Chart
From Apr 2024 to May 2024
Btg (LSE:BTG)
Historical Stock Chart
From May 2023 to May 2024